Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
270actual
Sites
102
Countries
Australia, Bulgaria, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-20 | actual | When the study began enrolling |
| Primary completion | 2025-11-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alcohol-related Liver Disease
Interventions
- Drug: NNC0194-0499
- Drug: Semaglutide
- Drug: NNC0194-0499 placebo
- Drug: Semaglutide placebo (Group A)
- Drug: Cagrilintide + semaglutide
- Drug: Cagrilintide
- Drug: Cagrilintide placebo
- Drug: Semaglutide placebo (Group B)
Primary outcome
what the primary-completion date above is the date OFChange in Enhanced Liver Fibrosis (ELF)
measured From week 0 to week 28
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed